X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GSK PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GSK PHARMA NOVARTIS/
GSK PHARMA
 
P/E (TTM) x 398.7 54.4 732.2% View Chart
P/BV x 31.9 10.8 295.6% View Chart
Dividend Yield % 1.4 2.7 53.7%  

Financials

 NOVARTIS   GSK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
GSK PHARMA
Mar-18
NOVARTIS/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs7582,760 27.5%   
Low Rs5792,040 28.4%   
Sales per share (Unadj.) Rs228.4339.0 67.4%  
Earnings per share (Unadj.) Rs31.741.4 76.6%  
Cash flow per share (Unadj.) Rs32.845.9 71.4%  
Dividends per share (Unadj.) Rs10.0035.00 28.6%  
Dividend yield (eoy) %1.51.5 102.6%  
Book value per share (Unadj.) Rs297.1242.9 122.3%  
Shares outstanding (eoy) m24.6984.70 29.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.97.1 41.3%   
Avg P/E ratio x21.157.9 36.3%  
P/CF ratio (eoy) x20.452.3 39.0%  
Price / Book Value ratio x2.29.9 22.8%  
Dividend payout %31.584.5 37.3%   
Avg Mkt Cap Rs m16,505203,280 8.1%   
No. of employees `0000.7NA-   
Total wages/salary Rs m1,4455,234 27.6%   
Avg. sales/employee Rs Th8,441.3NM-  
Avg. wages/employee Rs Th2,163.6NM-  
Avg. net profit/employee Rs Th1,173.1NM-  
INCOME DATA
Net Sales Rs m5,63928,715 19.6%  
Other income Rs m1,718545 315.0%   
Total revenues Rs m7,35729,260 25.1%   
Gross profit Rs m-635,059 -1.2%  
Depreciation Rs m25380 6.7%   
Interest Rs m552 2,765.0%   
Profit before tax Rs m1,5755,222 30.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m7921,892 41.8%   
Profit after tax Rs m7843,508 22.3%  
Gross profit margin %-1.117.6 -6.3%  
Effective tax rate %50.336.2 138.7%   
Net profit margin %13.912.2 113.7%  
BALANCE SHEET DATA
Current assets Rs m9,52221,815 43.6%   
Current liabilities Rs m3,29615,999 20.6%   
Net working cap to sales %110.420.3 545.1%  
Current ratio x2.91.4 211.9%  
Inventory Days Days3764 57.6%  
Debtors Days Days2819 152.1%  
Net fixed assets Rs m4612,475 0.4%   
Share capital Rs m123847 14.6%   
"Free" reserves Rs m7,21319,726 36.6%   
Net worth Rs m7,33620,573 35.7%   
Long term debt Rs m06 0.0%   
Total assets Rs m11,10539,475 28.1%  
Interest coverage x29.52,612.0 1.1%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.7 69.8%   
Return on assets %7.68.9 85.0%  
Return on equity %10.717.1 62.6%  
Return on capital %22.226.2 84.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m61564 10.7%   
Fx outflow Rs m3,6307,429 48.9%   
Net fx Rs m-3,570-6,865 52.0%   
CASH FLOW
From Operations Rs m1,6104,728 34.1%  
From Investments Rs m687-1,042 -65.9%  
From Financial Activity Rs m-2,677-3,066 87.3%  
Net Cashflow Rs m-380620 -61.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 2.0 10.2 19.6%  
FIIs % 1.6 23.8 6.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 15.4 139.6%  
Shareholders   41,647 102,036 40.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Ends 268 Points Higher(Closing)

After opening the day marginally higher, Indian share markets continued their momentum and ended their day on a positive note.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Mar 19, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS